(firstQuint)A Study of Cisapride in Patients With Symptomatic Gastro-Oesophageal Reflux Disease.

 This is a double-blind (neither patient nor study staff will know the identity of the assigned treatment) study evaluate the effectiveness and safety of cisapride in patients with gastro-oesophageal reflux disease (GORD) (also referred to as gastroesophageal reflux disease [GERD[) compared to a placebo (a identical in appearance to cisapride but does not contain active drug).

 Patients will receive placebo or cisapride suspension at 0.

2 mg/kg (volumn determined by patient weight) four times per day (q.

i.

d.

) (15 minutes before feeding 3 times a day and at bedtime) orally (by mouth) for 8 weeks.

.

 A Study of Cisapride in Patients With Symptomatic Gastro-Oesophageal Reflux Disease@highlight

The purpose of this study is to compare the efficacy and tolerability of cisapride with placebo in infants and children with gastro-oesophageal reflux disease (GORD).

